Funding for this research was provided by:
Pfizer (ID WS1948310)
Received: 30 June 2020
Accepted: 13 August 2020
First Online: 26 August 2020
Ethics approval and consent to participate
: The study was approved by the Regional Committee for Medical Research Ethics in South-Eastern Norway (REK number: 2012/101). All participating patients gave their written consent. The study was conducted in accordance with the Declaration of Helsinki, and all participants signed informed consent.
: Not applicable.
: The authors declare that they have no competing interests.